Article Details

Syros Pharmaceuticals (NASDAQ:SYRS) Receives Buy Rating from Cann

Retrieved on: 2018-08-17 00:07:30

Tags for this article:

Click the tags to see associated articles and topics

Syros Pharmaceuticals (NASDAQ:SYRS) Receives Buy Rating from Cann. View article details on hiswai:

Excerpt

<div><b>Two Sigma Investments</b> LP grew its position in Syros Pharmaceuticals by 80.3% during the 4th quarter. <b>Two Sigma Investments</b> LP now owns 21,197 ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up